Medical Oncology Fellowship Program

国家癌症研究所的成人医学肿瘤学奖学金培训计划是在国家癌症研究所(NCI)进行的临床肿瘤学和研究方面的统一教学经验。这一奖学金计划为对学术生涯感兴趣的医生提供了一个独特的机会来发展和整合他们的临床和基础研究兴趣。团契的临床部分包括住院和门诊患者的临床护理的主要责任，这些患者患有各种成人恶性肿瘤。它向参与者介绍了设计和进行临床试验的过程。在第一个临床年，重点是让研究员接触肿瘤学的基础科学和临床医学。在研究期间，这位研究员将加入国家癌症研究所数百名可用的研究人员之一，以获得必要的技能，成为一名独立的生物医学研究员，重点是实验室或临床科学。NCI努力保证其所有医学肿瘤学研究员至少有两年的受保护研究时间。该计划的目标是促进具有出色临床和研究技能的内科科学家的发展。在肿瘤内科培训的第一年，学员们将100%的时间投入到住院和门诊的临床培训中。所有第一年的研究员都在NIH临床中心(NIH-CC)、乔治敦大学和华盛顿医院中心工作。这确保了该计划的研究员扩展了他们在广泛范围的人类癌症方面的经验。第二年和第三年的剩余时间是任何NCI临床团队或任何NIH实验室进行研究的受保护时间。NIH-CC强调开发治疗癌症及其并发症的新方法。目前的临床重点领域包括前列腺癌、卵巢癌、肾细胞癌、淋巴瘤、霍奇金氏病、慢性白血病、新药试验、干细胞移植和艾滋病及其相关恶性肿瘤。艾滋病患者和艾滋病相关恶性肿瘤患者约占患者总数的15%；几乎所有这些患者都参与了实验性抗逆转录病毒化合物和化疗的研究。临床诊断程序的培训，如骨髓检查、胸腔穿刺术和穿刺术，是第一年经验的常规部分。与临床中心的相关临床单位，如放射肿瘤学、外科和重症监护医学的合作非常密切。医学肿瘤学分部还与国家心肺血液研究所血液学分会和NIH临床中心血液科合作开展了血液学/肿瘤学联合培训计划。该计划将血液学和内科肿瘤学的单独培训计划结合到一系列临床轮换中，包括FLOOR的前18或22个月的培训。主要兴趣是血液学的研究员在NHLBI有一个主要的任命，他们的主要临床暴露是临床血液学，但包括在NCI内科肿瘤科的六个月的临床肿瘤学。对医学肿瘤学有主要兴趣的研究员将被任命为NCI的成员。他们的主要临床接触是临床肿瘤学，另外还有6个月的血液学轮换。最初12个月的培训与内科肿瘤学完全一样--单独进行。在第二年，他们额外接受6个月的临床血液学检查，通常包括以下内容：2个月的血液科病房(NHLBI)，1个月的白血病服务(约翰·霍普金斯移植病房)，2周的输血药物治疗，6周的血液学和凝血咨询，以及1个月的华盛顿VA医院轮换。在完成这18个月的临床期间后，研究员在继续门诊临床工作的同时，进行长达4年的实验室或临床研究。整个计划提供与临床肿瘤学和癌症研究相关的讲座、研究研讨会、会议、期刊俱乐部、教学回合和会议。其中大多数是专门为医务人员研究员组织的。其中包括临床肿瘤学的核心课程讲座系列，全年每周举行一次会议，由高级工作人员就肿瘤疾病的各种问题提供讲座。研究员负责准备案例陈述和讲义材料。此外，整个国家卫生研究院每天举办10至15次研究研讨会和讲座；这些研讨会和讲座在每周一次的公告中公布，并定期向整个国家卫生研究院社区开放。

The Fellowship Training Program in Adult Medical Oncology at the National Cancer Institute is a unified teaching experience in clinical oncology and research that is conducted at the National Cancer Institute (NCI). This Fellowship Program provides a unique opportunity for physicians interested in academic careers to develop and integrate both their clinical and basic research interests. The clinical portion of the Fellowship consists of primary responsibility for the clinical care of inpatients and outpatients with a board spectrum of adult malignancies. It introduces the participants to the process of designing and conducting clinical trials. During the first clinical year, there is an emphasis on exposing fellows to the basic science and clinical medicine of oncology. During the research years, the fellow will join one of the several hundred available investigators within the National Cancer Institute to acquire the skills necessary to become an independent biomedical investigator with emphasis on laboratory or clinical science. The NCI works hard to guarantee at least two years of protected research time to all of its medical oncology fellows. The goal of the Program is to foster the development of physician-scientists who have excellent clinical and research skills. During the first year of Medical Oncology training, Fellows devote 100% of their time to clinical training in inpatient and outpatient care. All first year fellows spend time at the NIH Clinical Center (NIH-CC), Georgetown University and Washington Hospital Center. This ensures that fellows in the program extend their experience with a wide spectrum of human cancer. The remaining time in the second and third years is protected time for research in any of the NCI Clinical Teams or any NIH laboratory. The NIH-CC emphasizes the development of new approaches to the treatment of cancer and its complications. Current areas of clinical emphasis include prostate cancer, ovarian cancer, renal cell carcinoma, lymphomas, Hodgkin's disease, chronic leukemia, new drug testing, stem cell transplantation and AIDS, and its associated malignancies. Patients with AIDS and AIDS associated malignancies constitute approximately 15% of the total patient population; nearly all these patients are involved in studies of experimental antiretroviral compounds and chemotherapy. Training in clinical diagnostic procedures such as bone marrow examination, thoracentesis, and paracentesis is a routine part of the first-year experience. Collaboration with related clinical units in the Clinical Center such as Radiation Oncology, Surgery, and Critical Care Medicine is very close. The Medial Oncology Branch also has a joint Hematology/Oncology Training Program in collaboration with the Hematology Branch, National Heart, Lung, and Blood Institute, and the Hematology Department, Clinical Center, NIH. This program combines the separate training programs of hematology and medical oncology into a series of clinical rotations encompassing the first 18 or 22 months of fellow's training. Fellows whose principal interest is hematology have a primary appointment in the NHLBI and their chief clinical exposure is in clinical hematology but includes six months of clinical oncology in the Medical Oncology Branch, NCI. Fellows who have a primary interest in medical oncology have their appointment with the NCI. Their principal clinical exposure is in clinical oncology with an additional six months of hematology rotations. The first 12 months of training are exactly like that for medical oncology-alone. In the second year they undertake an additional 6 months of clinical hematology that usually includes the following: 2 months ward hematology (NHLBI), 1 month leukemia service (Johns Hopkins Transplant Unit), 2 weeks transfusion medicine, 6 weeks consult hematology and coagulation, and 1 month rotation at the Washington VA Hospital. Following completion of this 18-month clinical period, the fellow does laboratory or clinical research for up to 4 years of fellowship along with continued outpatient clinical duties. Offered throughout the Program are lectures, research seminars, conferences, journal club, teaching rounds and conferences relevant to clinical oncology and cancer research. Most of these are organized specifically for medical staff fellows. These include a core curriculum lecture series in clinical oncology, which meets once a week throughout the year, and offers lectures by members of the senior staff across the spectrum of issues in neoplastic disease. Fellows are responsible for preparing case presentations and lecture material. In addition, there are 10 to 15 research seminars and lectures given per day throughout the NIH; these are advertised in a weekly announcement and are regularly open to the entire NIH community.